Table 3 General demographic and clinical data in patients with and without restored circulatory efficiency (CircE)  after AVR
|  | not restored CircE (n = 10) | restored CircE (n = 31) | p-value |
|---|---|---|---|
Age (years) | 67 ± 7.8 | 66 ± 9.7 | 0.917 |
Male gender, n (%) | 7 (70%) | 14 (45%) | 0.172 |
Body mass index (kg/m2) | 28 ± 5.1 | 28 ± 4.0 | 0.580 |
BSA (m2) | 2 ± 0.3 | 2 ± 0.2 | 0.580 |
Prothesis size [mm] | 24 ± 2 | 23 ± 2 | 0.247 |
Biological prosthesis, n (%) | 10 (100%) | 29 (94%) | 0.410 |
Prosthesis type Medtronic biological, n (%) | 1 (10%) | 0 (0%) | 0.075 |
Prosthesis type Medtronic mechanical, n (%) | 0 (0%) | 1 (3%) | 0.565 |
Prosthesis type Edwards, n (%) | 2 (20%) | 7 (23%) | 0.864 |
Prosthesis type SJM regent, n (%) | 0 (0%) | 1 (3%) | 0.565 |
Prosthesis type Trifecta, n (%) | 5 (50%) | 16 (52%) | 0.929 |
Prosthesis type CE Perimount Magna Ease, n (%) | 2 (20%) | 6 (19%) | 0.964 |
Risk factors | |||
 Bicuspid aortic valve, n (%) | 8 (80%) | 23 (74%) | 0.710 |
 Dyslipidaemia, n (%) | 7 (70%) | 13 (42%) | 0.123 |
 Diabetes mellitus, n (%) | 2 (20%) | 2 (6%) | 0.209 |
 Arterial hypertension, n (%) | 8 (80%) | 21 (68%) | 0.459 |
 CCS III-VI, n (%) | 1 (10%) | 2 (6%) | 0.708 |
 NYHA III-IV, n [%] | 5 (50%) | 13 (42%) | 0.655 |
Medical Treatment | |||
 Betablocker, n (%) | 4 (40%) | 13 (42%) | 0.914 |
 Calcium antagonist, n (%) | 1 (10%) | 3 (10%) | 0.976 |
 Diuretics, n (%) | 3 (30%) | 8 (26%) | 0.795 |
 ARB, n (%) | 3 (30%) | 6 (19%) | 0.479 |
 ACE-I, n (%) | 4 (40%) | 7 (23%) | 0.280 |